Mesenchymal stromal cells: clinical challenges and therapeutic opportunities

By J. Galipeau, L. Sensébé. Cell Stem Cell, 2018

1,509 citations recorded by the source corpus.

Summary Mesenchymal Stromal Cells (MSCs) have been the subject of clinical trials for more than a generation and the outcomes of advanced clinical trials have fallen short of expectations raised by encouraging pre-clinical animal data in a wide array of disease models. In this perspective, important biological and pharmacological disparities in pre-clinical research and human translational studies are highlighted, and analysis of clinical trial failures and recent successes provide a rational pathway to MSC regulatory approval and deployment for disorders with unmet medical needs.

Subfields: Biomaterials, Genetics, Surgery

View Paper: https://www.semanticscholar.org/paper/91509724f2f75f3de63d143ecb452c9c9320ecbb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Zikuan Leng
2. Junfen Fan
3. F. Meng
4. Q. Han
5. Bo Yang
6. G. Shan
7. C. Caruso
8. W. Hou

Citations in the corpus

• Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia (2020, positive): “MSCs play a positive role mainly in two ways, namely immunomodulatory effects and differentiation abilities [16].”